Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CGC
CGC logo

CGC Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.944
Open
0.942
VWAP
0.91
Vol
4.86M
Mkt Cap
400.49M
Low
0.880
Amount
4.40M
EV/EBITDA(TTM)
148.18
Total Shares
448.28M
EV
383.04M
EV/OCF(TTM)
--
P/S(TTM)
1.06
Canopy Growth Corporation is a cannabis company, which produces, distributes, and sells a diverse range of cannabis and cannabis-related products for both adult-use and medical purposes. The Company brands include tweed, DOJA, LivRelief Infused, Deep Space, Ace Valley, 7ACRES, Vert, Twd, Wana, Hiway and Canopy Medical. The LivRelief Infused is transdermal creams contain a delivery system designed to penetrate a range of cannabidiol (CBD) and tetrahydrocannabinol (THC). The Deep Space offers beverages and gummies, containing the THC potency available in the Canadian market. The Ace Valley is a cannabis brand focused on ready-to-enjoy beverages. The 7ACRES offers products that are crafted by cannabis enthusiasts. The Wana gummies are created with a handcrafted recipe made with pectin, not gelatin, creating a gluten-free shelf-stable recipe that doesn’t melt. Its Canopy Medical is a pharmaceutical manufacturer for the production, import and release of medical cannabis products in Germany.
Show More

Events Timeline

(ET)
2026-03-27
07:40:00
Canopy Growth Appoints David Manner as Managing Director of Storz & Bickel
select
2026-03-19 (ET)
2026-03-19
11:20:00
Representative Proposes Bill to Protect Legal Cannabis Businesses
select
link
2026-02-13 (ET)
2026-02-13
08:50:00
Largest Indicative Borrow Rate Increases in Liquid Options
select
2026-02-06 (ET)
2026-02-06
16:30:00
Canopy Growth Files to Sell 18.71M Common Shares
select
2026-02-06
08:50:00
Significant Increases in Borrow Rates Among Liquid Option Names
select
2026-02-06
07:30:00
Company Reports Q3 Revenue of C$90.39M
select

News

Newsfilter
5.0
03-27Newsfilter
David Männer Appointed Managing Director of Storz & Bickel
  • Leadership Transition: David Männer will succeed Jürgen Bickel as Managing Director of Storz & Bickel effective April 1, 2026, following Bickel's 25 years of transformative leadership that established the company as a global leader in vaporization technology, indicating stability and continuity in the company's leadership.
  • Industry Benchmark: Since its founding in 2001, Storz & Bickel has set the standard for innovation, product quality, and design, earning ISO 13485 certification and the Dr. Rudolf Eberle Prize, which underscores its strong competitive position in the market as a benchmark for vapor quality.
  • Future Development: Incoming Managing Director Männer, a 14-year veteran of the company with deep operational knowledge and leadership skills, is expected to continue driving the company's expansion in the U.S. market and innovation efforts, further solidifying Storz & Bickel's market position.
  • Strategic Vision: Canopy Growth CEO Luc Mongeau stated that Männer's appointment will accelerate Storz & Bickel's growth, reflecting the company's ambitions in the global vaporization market and aiming to enhance brand influence through ongoing innovation.
Fool
9.5
03-21Fool
Canopy Growth and Sarepta Face Dismal Prospects
  • Canopy Growth's Financial Struggles: In Q3 of fiscal 2026, Canopy Growth reported flat net revenue of CA$75 million ($54.6 million) year-over-year, with a 49% improvement in the bottom line overshadowed by a net loss per share of CA$0.18 ($0.13), indicating ongoing financial distress.
  • Regulatory Challenges in Cannabis: The cannabis industry is fraught with heavy regulation and uncertainty, making future legal changes and market responses unpredictable, which casts a shadow over Canopy Growth's prospects and warrants caution from investors.
  • Sarepta Therapeutics' Drug Risks: Sarepta's Elevidys drug has faced significant challenges after causing the deaths of two patients due to liver failure; despite remedial actions, the company's Q4 2025 revenue fell 33% year-over-year to $442.9 million, reflecting worsening financial conditions.
  • Clinical Trial Failures: As Sarepta seeks full approval for other DMD drugs, recent confirmatory trial results have failed to meet primary endpoints, exacerbating investor concerns about its future, with the stock plummeting 79% over the past year.
Fool
2.0
03-09Fool
Canopy Growth's Stock Continues to Plummet
  • Market Value Collapse: Canopy Growth's market cap has plummeted from $14 billion five years ago to under $500 million today, indicating the company's ongoing struggles in the highly competitive Canadian cannabis market, resulting in significant investor losses.
  • Severe Financial Losses: Over the past 12 months, the company has incurred losses totaling CA$326.6 million, with CA$78.7 million burned through daily operations, reflecting a lack of profitability and deteriorating financial health.
  • Stagnant Revenue: In the most recent quarter ending December 31, 2025, the company's net revenue remained flat at CA$74.5 million, failing to achieve growth and exacerbating investor concerns about its future prospects.
  • Increased Investment Risk: While the stock may experience occasional spikes due to legalization news in the U.S., Canopy Growth lacks sustainable long-term growth reasons, making it a high-risk speculative stock that investors should approach with caution.
Fool
8.5
03-07Fool
Canopy Growth Stock Plummets 99% from All-Time High
  • Stock Price Collapse: Canopy Growth's stock is currently trading around $1 per share, down 99% from its all-time high of $568, indicating significant paper losses for investors who may need to consider selling to mitigate losses.
  • Intense Market Competition: Despite being a leader in the legal marijuana market, Canopy Growth faces fierce competition and ongoing illicit sales, which have hindered its ability to achieve sustainable profitability, negatively impacting its market performance.
  • Financial Restructuring: The company recently recapitalized its balance sheet, which has improved its financial position, but this action itself is not a positive sign, highlighting the financial pressures the company is under.
  • Acquisition Plans: Canopy Growth is working on an acquisition to be funded through a mix of cash and stock, which will strengthen its position in the medical marijuana space but will also dilute existing shareholders' equity, further impacting shareholder interests.
NASDAQ.COM
8.5
03-07NASDAQ.COM
Canopy Growth Acquires New Business Amid Challenges
  • Acquisition Deal: Canopy Growth is acquiring another marijuana business in a cash-and-stock transaction, which may weaken its balance sheet and dilute existing shareholders despite strengthening its position in the medical marijuana sector.
  • Market Competition: The legal marijuana market is highly competitive, with illicit sales persisting, putting pressure on Canopy Growth from unregulated competitors, even as it remains a leader in the Canadian market.
  • Financial Condition: The company recently recapitalized its balance sheet, improving its financial position, but the necessity of this action indicates ongoing instability in profitability.
  • Investor Advice: For investors who bought Canopy Growth stock recently, selling may not be necessary; however, those with significant paper losses from higher purchase prices might consider harvesting losses to offset capital gains taxes elsewhere in their portfolios.
Fool
9.5
03-03Fool
Canopy Growth's Stock Faces Grim Future Amid Mediocre Performance
  • Mediocre Financial Performance: Canopy Growth reported net revenue of CA$74.5 million ($54.5 million) for Q3 FY2026, remaining flat year-over-year, while the net loss per share improved from CA$1.11 ($0.81) to CA$0.18 ($0.13), primarily due to a reduction in share-based compensation, failing to indicate operational improvements.
  • Declining Free Cash Flow: The company's free cash flow for the quarter was approximately CA$19 million ($13.9 million), down from CA$28.2 million ($20.6 million) in the prior-year quarter, highlighting ongoing financial struggles and a lack of sustainable profitability.
  • Limited Regulatory Progress: Although President Trump’s executive order reclassifying cannabis to Schedule III may facilitate banking access and tax deductions for marijuana companies, the continued federal illegality of cannabis sales in the U.S. leaves Canopy Growth's market prospects bleak amid stiff competition.
  • Pessimistic Future Outlook: Even if federal legalization occurs, Canopy Growth's previous failures in the Canadian market suggest that success in the U.S. is unlikely, leading analysts to predict that the stock could eventually drop to zero, advising investors to exercise caution.
Wall Street analysts forecast CGC stock price to rise
4 Analyst Rating
Wall Street analysts forecast CGC stock price to rise
1 Buy
2 Hold
1 Sell
Hold
Current: 0.000
sliders
Low
1.03
Averages
2.52
High
5.90
Current: 0.000
sliders
Low
1.03
Averages
2.52
High
5.90
Canaccord
Buy
initiated
$2
AI Analysis
2026-03-27
New
Reason
Canaccord
Price Target
$2
AI Analysis
2026-03-27
New
initiated
Buy
Reason
Canaccord initiated coverage of Canopy Growth with a Buy rating and C$2 price target. Canopy is a leading cannabis company producing, distributing, and selling a "diverse range" of cannabis and cannabis-related products in key, global adult-use and medical cannabis markets, the analyst tells investors in a research note. The firm says the company's pivot from an asset-light, third-party supply model to an asset-right, in-house supply model will improve its global competitive positioning.
Alliance Global
Aaron Grey
Neutral
downgrade
2026-02-06
Reason
Alliance Global
Aaron Grey
Price Target
2026-02-06
downgrade
Neutral
Reason
Alliance Global analyst Aaron Grey lowered the firm's price target on Canopy Growth to C$1.80 from C$2.50 and keeps a Neutral rating on the shares following the fiscal Q3 report. The firm reduced the stock's multiple to reflect the potential impact from changes to veteran reimbursement and uncertainty around its gross margins.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CGC
Unlock Now

Valuation Metrics

The current forward P/E ratio for Canopy Growth Corp (CGC.O) is -4.66, compared to its 5-year average forward P/E of -3.59. For a more detailed relative valuation and DCF analysis to assess Canopy Growth Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.59
Current PE
-4.66
Overvalued PE
14.22
Undervalued PE
-21.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-294.06
Current EV/EBITDA
-336.53
Overvalued EV/EBITDA
443.79
Undervalued EV/EBITDA
-1031.91

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.86
Current PS
1.97
Overvalued PS
10.12
Undervalued PS
-0.40

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

top 5 penny stocks?
Intellectia · 91 candidates
Market Cap: 50.00M - 2.00BRegion: USPrice: $0.10 - $5.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Month Price Change Pct: $0.00 - $150.00Monthly Average Dollar Volume: >= 500,000
Ticker
Name
Market Cap$
top bottom
RXT logo
RXT
Rackspace Technology Inc
409.23M
KOS logo
KOS
Kosmos Energy Ltd
1.03B
IOVA logo
IOVA
Iovance Biotherapeutics Inc
1.14B
GERN logo
GERN
Geron Corp
1.20B
TRX logo
TRX
TRX Gold Corp
516.12M
AQST logo
AQST
Aquestive Therapeutics Inc
481.91M
Should I Buy cannabis stocks?
Intellectia · 9 candidates
Market Cap: >= 50.00MThemes: The Cannabis IndustryList Exchange: XNYS, XNASMonthly Average Dollar Volume: >= 100,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
4.06B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.29B
CRON logo
CRON
Cronos Group Inc
1.01B
TLRY logo
TLRY
Tilray Brands Inc
874.97M
CGC logo
CGC
Canopy Growth Corp
440.50M
SNDL logo
SNDL
SNDL Inc
386.25M
cannabis
Intellectia · 8 candidates
Market Cap: >= 200.00MPrice: >= $1.00Themes: The Cannabis IndustryIs Optionable: TrueMonthly Average Dollar Volume: >= 200,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
4.06B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.29B
CRON logo
CRON
Cronos Group Inc
1.01B
TLRY logo
TLRY
Tilray Brands Inc
874.97M
CGC logo
CGC
Canopy Growth Corp
440.50M
SNDL logo
SNDL
SNDL Inc
386.25M
stocks under $2 for day trade today
Intellectia · 158 candidates
Price: <= $2.00Volume: >= 500,000Price Change Pct: $-5.00 - $20.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
PHIO logo
PHIO
Phio Pharmaceuticals Corp
12.06M
PLUG logo
PLUG
Plug Power Inc
2.84B
BURU logo
BURU
NUBURU Inc
56.42M
TIRX logo
TIRX
Tian Ruixiang Holdings Ltd
10.04M
JTAI logo
JTAI
Jet.AI Inc
5.61M
BTBT logo
BTBT
Bit Digital Inc
563.19M
marijuana stocks
Intellectia · 8 candidates
Market Cap: >= 200.00MRegion: US, CanadaPrice: >= $1.00Themes: The Cannabis IndustryList Exchange: XNYS, XNAS, XASEIs Optionable: TrueMonthly Average Dollar Volume: >= 300,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
3.70B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.41B
TLRY logo
TLRY
Tilray Brands Inc
1.01B
CRON logo
CRON
Cronos Group Inc
999.35M
CGC logo
CGC
Canopy Growth Corp
460.70M
SNDL logo
SNDL
SNDL Inc
406.85M
stocks to buy for 1.19 i only have $10
Intellectia · 105 candidates
Price: <= $1.19Weekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
ASST logo
ASST
Strive Inc
1.11B
UP logo
UP
Wheels Up Experience Inc
624.57M
CAN logo
CAN
Canaan Inc
498.64M
CGC logo
CGC
Canopy Growth Corp
460.70M
DVLT logo
DVLT
Datavault AI Inc
433.82M
BYND logo
BYND
Beyond Meat Inc
424.50M
show me some penny stocks
Intellectia · 417 candidates
Market Cap: <= 500.00MPrice: <= $5.00Weekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
CAN logo
CAN
Canaan Inc
498.64M
LX logo
LX
Lexinfintech Holdings Ltd
498.06M
THM logo
THM
International Tower Hill Mines Ltd
494.77M
ORGO logo
ORGO
Organogenesis Holdings Inc
487.34M
GEVO logo
GEVO
Gevo Inc
487.04M
CLNE logo
CLNE
Clean Energy Fuels Corp
486.85M
Top cannabis stocks to buy
Intellectia · 9 candidates
Market Cap: >= 50.00MRevenue Ttm: >= 10.00MThemes: The Cannabis Industry
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
3.70B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.41B
TLRY logo
TLRY
Tilray Brands Inc
1.01B
CRON logo
CRON
Cronos Group Inc
999.35M
CGC logo
CGC
Canopy Growth Corp
460.70M
SNDL logo
SNDL
SNDL Inc
406.85M

Whales Holding CGC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Canopy Growth Corp (CGC) stock price today?

The current price of CGC is 0.8934 USD — it has decreased -2.93

What is Canopy Growth Corp (CGC)'s business?

Canopy Growth Corporation is a cannabis company, which produces, distributes, and sells a diverse range of cannabis and cannabis-related products for both adult-use and medical purposes. The Company brands include tweed, DOJA, LivRelief Infused, Deep Space, Ace Valley, 7ACRES, Vert, Twd, Wana, Hiway and Canopy Medical. The LivRelief Infused is transdermal creams contain a delivery system designed to penetrate a range of cannabidiol (CBD) and tetrahydrocannabinol (THC). The Deep Space offers beverages and gummies, containing the THC potency available in the Canadian market. The Ace Valley is a cannabis brand focused on ready-to-enjoy beverages. The 7ACRES offers products that are crafted by cannabis enthusiasts. The Wana gummies are created with a handcrafted recipe made with pectin, not gelatin, creating a gluten-free shelf-stable recipe that doesn’t melt. Its Canopy Medical is a pharmaceutical manufacturer for the production, import and release of medical cannabis products in Germany.

What is the price predicton of CGC Stock?

Wall Street analysts forecast CGC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGC is2.52 USD with a low forecast of 1.03 USD and a high forecast of 5.90 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Canopy Growth Corp (CGC)'s revenue for the last quarter?

Canopy Growth Corp revenue for the last quarter amounts to 74.54M USD, decreased -0.29

What is Canopy Growth Corp (CGC)'s earnings per share (EPS) for the last quarter?

Canopy Growth Corp. EPS for the last quarter amounts to -0.18 USD, decreased -83.78

How many employees does Canopy Growth Corp (CGC). have?

Canopy Growth Corp (CGC) has 960 emplpoyees as of March 30 2026.

What is Canopy Growth Corp (CGC) market cap?

Today CGC has the market capitalization of 400.49M USD.